Study	Events Tota	I	Proportion	95%-CI	Weight
<b>CAR T-cell therapy</b> Bishop et al, 2022 Locke et al, 2022 Kamdar et al, 2022 <b>Random effects model</b> Heterogeneity: $I^2 = 97\%$ , $\tau^2 = 0$	46 162 117 180 61 92 <b>43</b> 4 0.0450, <i>p</i> < 0.01		0.65 0.66	[0.22; 0.36] [0.58; 0.72] [0.56; 0.76] <b>[0.29; 0.78]</b>	4.2% 4.2% 4.0% <b>12.4%</b>
Crump et al, 2014 Crump et al, 2014 Imhoff et al, 2017 Kuhnl et al, 2020 Kang et al, 2008 Imhoff et al, 2017 Fayad et al, 2015 Witzig et al, 2015 Witzig et al, 2017 Bishop et al, 2022 Matasar et al, 2013 Locke et al, 2022 Gisselbrecht et al, 2010 Gisselbrecht et al, 2010 Kamdar et al, 2022 Witzens-Harig et al, 2021 Matasar et al, 2013 Gyan et al, 2021 Random effects model Heterogeneity: $I^2 = 87\%$ , $\tau^2 = 0$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$		$\begin{array}{c} 0.14\\ 0.15\\ 0.16\\ 0.20\\ 0.22\\ 0.23\\ 0.24\\ 0.27\\ 0.28\\ 0.31\\ 0.32\\ 0.36\\ 0.39\\ 0.39\\ 0.39\\ 0.39\\ 0.40\\ 0.42\\ 0.44\\ 0.49\\ \end{array}$	[0.10; 0.18] [0.11; 0.19] [0.11; 0.21] [0.03; 0.40] [0.04; 0.48] [0.16; 0.28] [0.14; 0.34] [0.15; 0.35] [0.15; 0.42] [0.21; 0.35] [0.26; 0.40] [0.29; 0.43] [0.29; 0.43] [0.29; 0.50] [0.26; 0.54] [0.23; 0.63] [0.31; 0.66] <b>[0.23; 0.33]</b>	4.4% 4.4% 3.3% 2.9% 4.3% 4.0% 4.0% 3.7% 4.2% 4.2% 4.2% 4.2% 4.2% 4.2% 4.0% 3.6% 3.6% 3.3% <b>73.2%</b>
Others Wagner-Johnston et al, 2018 Coyle et al, 2020 Wang et al, 2013 Kuhnl et al, 2020 <b>Random effects model</b> Heterogeneity: $I^2 = 15\%$ , $\tau^2 = 0$ <b>Random effects model</b> Heterogeneity: $I^2 = 93\%$ , $\tau^2 = 0$ Test for subgroup differences:	9 4 10 4 7 2 0.0008, p = 0.32 2924 0.0188, p < 0.01		0.22 0.22 0.33 <b>0.20</b>	[0.07; 0.25] [0.11; 0.38] [0.11; 0.37] [0.15; 0.57] <b>[0.13; 0.27]</b>	4.1% 3.7% 3.7% 2.9% 14.4%

**S3 Fig.** Pooled complete response rate according to the treatment categories in ASCT-eligible trials [1-17]. ASCT, autologous stem-cell transplantation; CAR, chimeric antigen receptor.